Related Experiment Video

Updated: Jun 14, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting

Olivier Cuvillier1, Isabelle Ader, Pierre Bouquerel

  • 1CNRS, Institut de Pharmacologie et de Biologie Structurale, Toulouse, F-31000 France. cuvillio@me.com

Current Molecular Pharmacology
|March 23, 2010
PubMed

Insights

Sphingolipid metabolism regulates cancer. Sphingosine kinase-1 (SK1) produces pro-survival sphingosine 1-phosphate (S1P) and reduces pro-apoptotic sphingolipids, making the SK1/S1P pathway a potential cancer therapy target.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Biology

Background:

  • Sphingolipids, including ceramide, sphingosine, and sphingosine 1-phosphate (S1P), are key regulators of cellular processes.
  • An imbalance in sphingolipid metabolism is implicated in cancer development and progression.
  • Sphingosine kinase-1 (SK1) plays a critical role in controlling the balance between pro-apoptotic and pro-survival sphingolipids.

Purpose of the Study:

  • To investigate the role of sphingosine kinase-1 (SK1) in cancer.
  • To explore the sphingosine kinase-1/sphingosine 1-phosphate (S1P) signaling pathway as a potential therapeutic target in oncology.

Main Methods:

  • The abstract does not specify the methods used.
  • The study focuses on the regulatory functions of sphingolipid metabolites and enzymes.

Main Results:

  • Sphingosine 1-phosphate (S1P) promotes cell proliferation, survival, and angiogenesis.
  • Ceramide and sphingosine induce apoptosis and cell growth arrest.
  • Sphingosine kinase-1 (SK1) produces S1P and reduces ceramide and sphingosine levels.
  • SK1 gene is oncogenic, its mRNA is overexpressed in tumors, and its overexpression confers resistance to apoptosis.
  • SK1 activity is downregulated by anti-cancer treatments.

Conclusions:

  • The sphingosine kinase-1/sphingosine 1-phosphate (S1P) signaling pathway is a critical regulator of cellular fate in cancer.
  • Dysregulation of SK1/S1P signaling contributes to cancer progression.
  • Targeting the SK1/S1P pathway holds promise for novel cancer therapeutics.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...